Patient P-02571

Synthetic patientMETA-24 · Day 177 · 75+ · F · baseline S11Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S11
Day 22 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 83 ME-01 recommended — Monitoring Escalation ME-01
Day 84 Patient accepted — Started ME-01 in the companion
Day 87 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 22.

Primary contributors, last 14 days

GI instability+13
Nutritional resilience-6
Inflammatory activity+4

What helped?

Monitoring Escalation ME-01Day 83
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
89% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 64
- WearableHRV 23 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 77 bpm
- Wearable568 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 77 and rising
- WearableSleep 5.8 h, below personal baseline
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 46

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2 · butyrate capacity 48/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 22 ms
Sleep: 5.9 h
Steps: 1,334
Resting HR: 76 bpm

Daily log: GI score 77, nutritional resilience 35, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02511	50%	S04	—	—	51
P-02594	50%	S20	—	—	45
P-02610	50%	S14	NP-02	no change	42
P-02146	49%	S14	ME-01	improved	33
P-02157	46%	S14	ME-01	improved	55
P-02320	45%	S14	NP-02	improved	50
P-02514	45%	S05	ME-01	improved	44
P-02532	45%	S14	—	—	58
P-02546	45%	S20	NP-02	improved	40
P-02614	45%	S14	—	—	39
P-02505	44%	S14	NP-02	improved	45
P-02582	44%	S14	ME-01	improved	45